RxDoctor Payments Data

Korie Lambert

Physician Assistant · Huntersville, NCNPI 1396709564

Payments from drug & device makers

$973in general payments, 2019–2025

Across 30 payments — averaging $32.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$625
  • Lilly USA, LLC$138
  • Bayer$58
  • Pfizer$44
  • Johnson & Johnson$28
  • Organon$18
  • plus $63 from 4 others

What the payments were for

  • Food & beverage$90993%
  • Education$647%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk13$625
Lilly USA, LLC4$138
Bayer4$58
Pfizer2$44
Johnson & Johnson(2 entities)2$28
Organon1$18
Amgen1$17
GSK1$17
AbbVie1$16
Esperion Therapeutics, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$973 in reported general payments places this provider in the 65th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$35,637
Medicare patients
81
Services billed
761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$58,991
MounjaroTirzepatide28$31,733
Tresiba Flextouch U-200Insulin Degludec12$13,366
JardianceEmpagliflozin11$12,740
FarxigaDapagliflozin Propanediol13$11,238
EliquisApixaban11$10,046
Tresiba Flextouch U-100Insulin Degludec16$7,636
ValacyclovirValacyclovir Hcl20$2,314
PremarinEstrogens, Conjugated11$2,193
Atorvastatin Calcium124$1,189
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic12$1,127
Omeprazole45$810
Hydroxyzine Hcl17$764
Rosuvastatin Calcium97$707
Bupropion XlBupropion Hcl38$658

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$625$58,99152 claims
Lilly USA, LLCMounjaro$138$31,73328 claims
PfizerEliquis, Premarin$44$12,23922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Huntersville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →